# A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)

Source: https://onco.cc/trials/nct05788926/  
OnCo record `nct05788926` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of TG6050 run by Transgene, terminated.

## Summary

A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) is a phase 1 interventional study registered as NCT05788926 by Transgene, with 22 participants enrolled, started 2023-04-05. Conditions recorded: Non-small Cell Lung Cancer. Interventions recorded: TG6050.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05788926
- Phase: 1
- Setting: A Phase I Dose-escalation Trial of TG6050 Administered by Intravenous Infusion in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Transgene
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT05788926: https://clinicaltrials.gov/study/NCT05788926

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [TG6050](https://onco.cc/drugs/tg6050/)
- companies: [Transgene](https://onco.cc/companies/transgene/)

---
JSON: https://onco.cc/api/v1/entities/nct05788926.json